These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6635442)

  • 61. Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.
    Van der Auwera P; Joly P
    J Antimicrob Chemother; 1987 Mar; 19(3):313-20. PubMed ID: 3032884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High-level oxacillin and gentamycin resistance with reduced susceptibility to vancomycin in Staphylococcus aureus-carrying mecA and femA gene complex.
    Raju S; Kelmani Chandrakanth R; Patil SA
    Curr Microbiol; 2007 Jun; 54(6):429-34. PubMed ID: 17457646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus.
    Fabry W; Kock HJ
    J Hosp Infect; 2014 Jan; 86(1):68-72. PubMed ID: 24286853
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro.
    Goh S; Loeffler A; Lloyd DH; Nair SP; Good L
    BMC Microbiol; 2015 Nov; 15():262. PubMed ID: 26560174
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.
    Baltch AL; Bassey C; Fanciullo G; Smith RP
    J Antimicrob Chemother; 1987 Jan; 19(1):45-8. PubMed ID: 3104277
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oxacillin-induced inhibition of protein and RNA synthesis in a tolerant Staphylococcus aureus isolate.
    Jablonski PE; Mychajlonka M
    J Bacteriol; 1988 Apr; 170(4):1831-6. PubMed ID: 2450870
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protection of staphylococci ingested by macrophages from the bactericidal action of rifampin.
    Pesanti EL
    Antimicrob Agents Chemother; 1980 Jul; 18(1):208-9. PubMed ID: 7416746
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A note on the effect of gamma-rays on cefamandole and oxacillin.
    Jacobs GP; Dobrilovic L; Raghavan N; Carpenter D
    Int J Rad Appl Instrum A; 1987; 38(1):71-3. PubMed ID: 3030972
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synergy assessed by checkerboard. A critical analysis.
    Hsieh MH; Yu CM; Yu VL; Chow JW
    Diagn Microbiol Infect Dis; 1993; 16(4):343-9. PubMed ID: 8495592
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Profound Neutropenia with Concomitant Hepatitis During Oxacillin Therapy.
    Miller JB; Gelber AC
    Cureus; 2019 Jan; 11(1):e3823. PubMed ID: 30868036
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Precautions on rifampin.
    Shabino C
    West J Med; 1989 Jan; 150(1):50. PubMed ID: 18750518
    [No Abstract]   [Full Text] [Related]  

  • 72. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis.
    Adema JL; Ahiskali A; Fida M; Mediwala Hornback K; Stevens RW; Rivera CG
    Pathogens; 2023 May; 12(5):. PubMed ID: 37242373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.
    Garzoni C; Uçkay I; Belaieff W; Breilh D; Suvà D; Huggler E; Lew D; Hoffmeyer P; Bernard L
    Springerplus; 2014; 3():287. PubMed ID: 25019039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
    Thwaites G; Auckland C; Barlow G; Cunningham R; Davies G; Edgeworth J; Greig J; Hopkins S; Jeyaratnam D; Jenkins N; Llewelyn M; Meisner S; Nsutebu E; Planche T; Read RC; Scarborough M; Soares M; Tilley R; Török ME; Williams J; Wilson P; Wyllie S; Walker AS;
    Trials; 2012 Dec; 13():241. PubMed ID: 23249501
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.
    Mackenzie AM; Macdonald NE
    Can J Infect Dis; 1990; 1(2):41-7. PubMed ID: 22553438
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rifampin combination therapy for nonmycobacterial infections.
    Forrest GN; Tamura K
    Clin Microbiol Rev; 2010 Jan; 23(1):14-34. PubMed ID: 20065324
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.
    Riedel DJ; Weekes E; Forrest GN
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2463-7. PubMed ID: 18474578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intracardiac device and prosthetic infections: What do we know?
    Johnston LB; Conly JM
    Can J Infect Dis Med Microbiol; 2004 Jul; 15(4):205-9. PubMed ID: 18159493
    [No Abstract]   [Full Text] [Related]  

  • 79. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.
    Van der Auwera P; Klastersky J; Thys JP; Meunier-Carpentier F; Legrand JC
    Antimicrob Agents Chemother; 1985 Oct; 28(4):467-72. PubMed ID: 3907494
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus.
    Van der Auwera P; Klastersky J
    Rev Infect Dis; 1983; 5 Suppl 3():S509-14. PubMed ID: 6635442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.